Journal
CURRENT OPINION IN RHEUMATOLOGY
Volume 18, Issue 6, Pages 606-613Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.bor.0000245727.40630.c3
Keywords
autoantibodies; classification; localized scleroderma; morphoea; organ involvement
Categories
Ask authors/readers for more resources
Purpose of review Localized scleroderma, also known as morphoea, has a variety of clinical manifestations that can include systemic involvement. Early recognition, diagnosis and treatment may improve the long-term outcome. Recent findings A large multicentre study coordinated by the Pediatric Rheumatology European Society has yielded important information on the epidemiology and clinical manifestations of juvenile localized scleroderma, especially as it pertains to systemic manifestations. Previous results using methotrexate and corticosteroids have been confirmed. Studies on phototherapy have also demonstrated efficacy. A new immunomodulator, imiquimod, has shown promise in an initial case series. Summary Studies over the past year highlight the wide range of extracutaneous manifestations and different forms of localized scleroderma and suggest that treatment may be beneficial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available